Bio Pharma Dive
SEPTEMBER 9, 2020
The median CEO of 231 drug companies analyzed by BioPharma Dive earned 50% more last year than in 2017, a leap that far outpaced the more modest pay gains among employees.
BioPharma Reporter
SEPTEMBER 7, 2020
Venom from honeybees has been found to rapidly destroy triple-negative breast cancer and HER2-enriched breast cancer cells â with minimal effect on healthy cells, according to a study published this month.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
pharmaphorum
SEPTEMBER 10, 2020
Two UK biotechs – Destiny Pharma and Sporegen – have joined forces to develop a nasal spray that they say could serve as a first line of defense against coronavirus infections. The nasal spray could provide protection from infection within a few days of administration, and would be easy to make in bulk at a low cost, say the partners. The programme is still in the early stages of development, but if it works in trials would provide another approach to prevent transmission of SARS-CoV-2, the viru
Camargo
SEPTEMBER 9, 2020
With smartphones now ubiquitous, interest has increased in digital health solutions such as telemedicine platforms. The post Prescription Digital Therapeutics: When Software Is the Active Ingredient appeared first on Camargo.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Bio Pharma Dive
SEPTEMBER 8, 2020
A participant in a clinical trial of the experimental shot suffered from an unexplained illness, triggering an investigation and a pause in vaccinations.
Pharma Times
SEPTEMBER 9, 2020
The drug's cost-effectiveness estimate when used in the maintenance setting is uncertain, the Institute has concluded
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
BioSpace
SEPTEMBER 8, 2020
Preclinical data for Pfizer and BioNTech’s Phase II/III COVID-19 mRNA vaccine candidate generated BNT162b2 strong anti-viral effects against an infectious SARS-CoV-2 challenge.
Bio Pharma Dive
SEPTEMBER 10, 2020
With BioMarin's gene therapy sidelined, attention is turning to other drugs, including one Sanofi acquired when it paid $11.6 billion for Bioverativ.
BioPharma Reporter
SEPTEMBER 9, 2020
Two US government agencies are investigating whether Moderna Therapeutics, the biotech company behind one of the leading Covid-19 vaccine candidates, was upfront about government funding in its filed or awarded patents, as required by federal law.
pharmaphorum
SEPTEMBER 7, 2020
Laura Morrill from ECI Partners looks at why data and technology are the keys to success in pharma services post-COVID. The pharmaceuticals industry has, for some time, been behind the curve when it comes to the adoption of technology. High barriers to entering the sector and high levels of regulation are just two factors that have meant that there has often been an “innovation lag” when it comes to implementing new technologies and embracing technological and digital change in the pharma indust
BioSpace
SEPTEMBER 6, 2020
SARS was called the first pandemic of the 21st century. It would not be the last. Nor would it be the most deadly.
Bio Pharma Dive
SEPTEMBER 10, 2020
A new request from the regulator could tighten the race between Sarepta and Pfizer to prove out a gene therapy for Duchenne muscular dystrophy.
Outsourcing Pharma
SEPTEMBER 8, 2020
The company has submitted an investigational new drug application for FSD201, a possible therapy for patients with severe cases of the virus.
pharmaphorum
SEPTEMBER 11, 2020
Brent Saunders has been out of the limelight for a few months since departing Allergan after its takeover by AbbVie, but now he is back in a leading role at Vesper Healthcare Acquisition, set up to acquire assets in the healthcare sector. Delaware-incorporated Vesper has filed a with a $400 million initial public offering (IPO) and plans to list on the Nasdaq under the symbol VSRU, with Goldman Sachs and JP Morgan acting as bookrunners.
Advertisement
White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations
BioSpace
SEPTEMBER 9, 2020
In July, the study was paused after another patient experienced neurological issues.
Bio Pharma Dive
SEPTEMBER 10, 2020
ZS surveyed more than 500 physicians, 500 patients and 30 healthcare administrators to gather their current thoughts on care delivery, telemedicine and pharma's potential role during the COVID-19 pandemic.
BioPharma Reporter
SEPTEMBER 7, 2020
The Australian Government has made a $1.7bn AUD ($1.34bn USD) supply and production agreement for COVID-19 vaccines: with the first doses set to come from AstraZenecaâs vaccine in January 2021.
pharmaphorum
SEPTEMBER 8, 2020
An EU consumer body has urged the European Commission to keep compensation measures in place for people who might be harmed in COVID-19 vaccine trials, responding to reports that the drug industry is lobbying to reduce liability. In a letter to the Commissioner for Health and Food Safety Stella Kyriakides, the BEUC says that even though the need for a coronavirus vaccine is urgent, access “must go hand in hand with adequate consumer compensation in case of harm.”.
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
BioSpace
SEPTEMBER 7, 2020
The CEOs of AstraZeneca, BioNTech, GlaxoSmithKline, Johnson & Johnson, Moderna, Novavax, Pfizer, Merck and Sanofi all signed the pledge promising to ensure that any vaccine put forth by one or more of the companies meets the rigorous standards for approval.
Bio Pharma Dive
SEPTEMBER 8, 2020
In an unusual letter, the heads of nine top vaccine developers pledged to "stand with science" and only move forward with approval applications if warranted by clinical results.
Outsourcing Pharma
SEPTEMBER 8, 2020
The collaboration combines two solutions to help pharma and healthcare providers deal with myriad challenges associated with limited drug supplies.
pharmaphorum
SEPTEMBER 10, 2020
September is Global Diversity and Inclusion month – David Peacock, managing director of MSD in the UK shares with us his insights on why diversity and inclusion is so important and why it is critical to the future success of the life sciences sector. Taking diversity and inclusion seriously, supported by robust policies and accountability for implementation, creates success for everyone, fostering happy, healthy and invested employees, new ways of thinking and opportunities for growth, learning
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
BioSpace
SEPTEMBER 8, 2020
A study published in Nature Communications on August 27 shows that a feline antiviral drug was effective at inhibiting the replication of human coronaviruses in cell cultures infected by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
Bio Pharma Dive
SEPTEMBER 9, 2020
Widening the number of eligible patients could make Intra-Cellular's schizophrenia pill a blockbuster, analysts forecast.
Pharma Times
SEPTEMBER 10, 2020
The proposed deal covers the initial supply of 200 million doses and an option to purchase an additional 100 million, with deliveries starting by the end of 2020, if the vaccine is approved
pharmaphorum
SEPTEMBER 7, 2020
A trial of Russia’s Sputnik V coronavirus vaccine has shown the jab produces an immune response, although the study was too small to produce conclusive findings, particularly on safety. Preliminary results published in The Lancet are from a non-randomised phase 1/2 trial of 76 people aged 18-60, which found an antibody response within 21 days and no serious adverse events after 42 days.
BioSpace
SEPTEMBER 8, 2020
In people with diabetes, periods of high blood sugar can negatively impact their health years later, even if they get their blood sugar under control. While this ‘metabolic memory’ phenomenon has been known for years, why it happens is poorly understood.
Bio Pharma Dive
SEPTEMBER 11, 2020
The trials, which involve Bristol Myers and Pfizer's Eliquis as well as other anticoagulants, follow mounting evidence of blood clotting in COVID-19 patients.
Pharma Times
SEPTEMBER 7, 2020
The personalised cancer treatment has received conditional approval in the US
pharmaphorum
SEPTEMBER 9, 2020
Geneticist Dr Charles Steward has spent his career studying the human genome – but his work became much more personal when his children were diagnosed with severe neurological diseases. Charlie told pharmaphorum how his search for a genetic cause has led him to straddle the divide between scientist and patient advocate. For some people, a job is more than just a job.
Advertisement
This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.
Expert insights. Personalized for you.
361 
Let's personalize your content